Wedbush Initiates Coverage On Werewolf Therapeutics with Outperform Rating, Announces Price Target of $9
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll has initiated coverage on Werewolf Therapeutics (NASDAQ:HOWL) with an Outperform rating and a price target of $9.
August 24, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Werewolf Therapeutics has been given an Outperform rating by Wedbush with a price target of $9.
The Outperform rating from Wedbush indicates a positive outlook for Werewolf Therapeutics. The price target of $9 suggests potential upside for the stock. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100